Zanosar
(streptozocin)Phase 2Small molecule
TevaZanosar is one of 49 small molecule programs targeting Chemotherapy. It is currently in Phase 2.
1
Indications
5
Total Trials
1
Active Trials
48
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
104 competitors in Chemotherapy
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Eloxatin
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Cytosar
TevaPhase 3
Avastin
RochePhase 3
Vepesid
AAvyxa
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Imfinzi
AstraZenecaPhase 3
Gemzar
Johnson & JohnsonPhase 3
Beyfortus
BeiGenePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Brain Neoplasm1 trial
Metastatic Neuroendocrine Tumor1 trial
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
Completed·—·Phase 2·NCT00602082·84 enrolled
Colorectal Cancer1 trial
Locally Advanced1 trial
Regulatory
FDA Approval Timeline[4]
May 7, 1982
ZANOSAR
NDA NDA050577
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for streptozocin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]